Metilfenidato Farmoz (Methylphenidate Hydrochloride)

Metilfenidato Farmoz is a central nervous system stimulant used in the management of specific neurobehavioral disorders.

• Attention deficit hyperactivity disorder (ADHD): improves attention, reduces hyperactivity and impulsivity in diagnosed individuals.
• Narcolepsy: decreases excessive daytime sleepiness and improves wakefulness.
• Executive function deficits in ADHD: supports better task organization and completion in patients with attention challenges.

• Methylphenidate inhibits the reuptake of dopamine and norepinephrine by blocking their transporters, leading to increased synaptic concentrations of these neurotransmitters. The heightened dopaminergic and noradrenergic activity in the prefrontal cortex enhances neuronal signaling associated with attention, impulse control, and wakefulness, thereby addressing the core symptoms of ADHD and narcolepsy.

Methylphenidate may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Insomnia: difficulty falling or staying asleep.
• Decreased appetite: reduced hunger leading to weight loss.
• Headache: mild to moderate cranial discomfort.
• Stomach pain: abdominal discomfort or cramps.
• Nausea: feeling of queasiness or urge to vomit.
• Irritability: increased mood swings or agitation.

Serious or Rare Side Effects

• Cardiovascular events: hypertension, tachycardia, or arrhythmia.
• Psychosis: hallucinations or delusional thinking.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Priapism: prolonged, painful erection.
• Seizures: convulsive episodes in susceptible individuals.
• Mood disorders: emergence of severe depression or suicidal thoughts.

When prescribing or dispensing Metilfenidato Farmoz, several safety considerations are essential.

• Cardiovascular assessment: evaluate history of heart disease, hypertension, or arrhythmias before initiating therapy.
• Psychiatric monitoring: watch for new or worsening anxiety, mood swings, or psychotic symptoms.
• Growth monitoring in children: regularly track height and weight to detect potential growth suppression.
• Potential for abuse: use only as prescribed and educate patients about dependence risk.
• Drug interactions: review all concomitant medications for possible pharmacodynamic or pharmacokinetic conflicts.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Methylphenidate can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): may precipitate hypertensive crisis.
• Alpha‑adrenergic agonists (e.g., clonidine): can cause severe hypertension when combined.
• Tricyclic antidepressants: increase risk of cardiovascular adverse events.

Moderate Interactions (Monitor Closely)

• Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs): may elevate serotonin levels.
• Antihypertensive agents: methylphenidate may reduce their efficacy, requiring dose adjustment.
• Anticonvulsants (e.g., carbamazepine): may alter methylphenidate plasma concentrations.